Xponance Inc. Acquires 5,402 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Xponance Inc. lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 16.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 38,696 shares of the biopharmaceutical company’s stock after acquiring an additional 5,402 shares during the period. Xponance Inc.’s holdings in Royalty Pharma were worth $987,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Swedbank AB grew its position in Royalty Pharma by 10.3% in the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock valued at $310,308,000 after acquiring an additional 1,136,800 shares during the last quarter. State Street Corp grew its holdings in shares of Royalty Pharma by 0.3% during the 3rd quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company’s stock valued at $269,215,000 after purchasing an additional 29,451 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Royalty Pharma by 6.1% during the 3rd quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock valued at $205,562,000 after purchasing an additional 417,490 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Royalty Pharma by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company’s stock worth $79,888,000 after purchasing an additional 130,025 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its stake in Royalty Pharma by 44.7% in the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock valued at $85,809,000 after purchasing an additional 936,900 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Royalty Pharma presently has an average rating of “Buy” and an average target price of $41.60.

Royalty Pharma Trading Up 0.6 %

RPRX opened at $33.70 on Monday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20. The company’s 50 day moving average price is $32.25 and its two-hundred day moving average price is $28.71. The firm has a market capitalization of $19.43 billion, a price-to-earnings ratio of 23.24, a PEG ratio of 2.31 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were given a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.61%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.